Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10724239 | 0.90 | EPHX1 (0.48) | NPC1RAB9AEPHX1HPGDSMN1; SMN2 | |
| SCHEMBL12606810 | 0.87 | EPHX1 (0.41) | EPHX1SMN1; SMN2ACHE | |
| SCHEMBL12640901 | 0.85 | NPC1 (0.42) | NPC1RAB9AEPHX1CASP1HPGD | |
| SCHEMBL8322165 | 0.85 | EPHX1 (0.44) | NPC1RAB9AEPHX1HPGDSMN1; SMN2 | |
| SCHEMBL9359582 | 0.82 | ACHE (0.45) | NPC1RAB9AEPHX1HPGDSMN1; SMN2 | |
| SCHEMBL17224252 | 0.82 | ACHE (0.47) | NPC1RAB9AEPHX1HPGDSMN1; SMN2 | |
| SCHEMBL19145239 | 0.82 | EPHX1 (0.42) | NPC1RAB9AEPHX1HPGDSMN1; SMN2 | |
| SCHEMBL17175563 | 0.81 | EPHX1 (0.39) | NPC1RAB9AEPHX1SMN1; SMN2ACHE | |
| SCHEMBL15854874 | 0.80 | EPHX1 (0.56) | EPHX1ACHE | |
| SCHEMBL16751335 | 0.80 | PCNA (0.38) | RAB9AHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079051-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | NPC1 4614/4885RAB9A 1084/4885EPHX1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.